The agreement sealed with Elanco Animal Health will allow Hipra to introduce two essential vaccines against avian metapneumovirus (aMPV) into the North American market. This virus is highly contagious and primarily affects turkeys, as well as broiler chickens and laying and breeding birds.
The vaccines, named RESPIVAC® aMPV and HIPRAVIAR® TRT, were successfully tested during field trials conducted in 2025 with selected poultry farmers. The results showed a significant improvement in the health of vaccinated birds, allowing distribution to begin in the US with guaranteed continuous supply.
Vaccination is fundamental to controlling the virus, as biosecurity practices alone are not sufficient to curb the spread, which can affect between 60 and 80% of the country's commercial flocks.
These two solutions offer cross-protection between virus subtypes A and B and stand out for their flexible administration methods. They can be applied in various ways, including in the hatchery, on the farm, during laying, by spray, or through drinking water.
Hipra emphasizes that the alliance with Elanco not only ensures a constant supply in the United States but also consolidates its global strategy in animal health, providing preventive solutions worldwide.
